Waldenstrom Macroglobulinemia – Epidemiology – Mature markets

Clarivate Epidemiology’s coverage of Waldenstrom macroglobulinemia (WM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of WM and non-WM, non-gamma heavy chain disease (gHCD) LPL for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s WM and non-WM, non-gHCD LPL forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with WM and non-WM, non-gHCD LPL per year?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of WM and non-WM, non-gHCD LPL over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following WM and non-WM, non-gHCD LPL. subpopulations:

• Diagnosed incident cases of WM
• Diagnosed incident cases of non-WM, non-gHCD LPL
• Diagnosed incident cases of WM based on symptom status
• Diagnosed prevalent cases of WM
• Diagnosed prevalent cases of non-WM, non-gHCD LPL
• Diagnosed drug-treatable cases of WM

Note: Coverage may vary by country.